FW

Active Director Director DIN 09163024
DIN 09163024 First appointment Apr 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2021
Shareholding value •••• Premium profile

About Feng Wei

Data last updated:

Feng Wei is a Director at Bld Pharmatech (India) Private Limited (since 2021). The company operates in Pharma. Bld Pharmatech (India) Private Limited reported revenue of ₹137 Cr (FY 2025).

DIN 09163024
Primary Designation Director
Industry Pharma
First Appointment 30 Apr 2021
Oldest Company Age 7 yrs
Largest company Bld Pharmatech (India) Private Limited · ₹137 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Apr 20212019₹137 Cr (FY 2025)Active

Board colleagues of Feng Wei

NameDINCompanyDesignation
Chandan Mahendra Bhatera03282004Bld Pharmatech (India) Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Bld Pharmatech (India) Private Limited
Premium access

Shareholding and investment profile for Feng Wei

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Feng Wei

Feng Wei currently holds 1 directorship: Bld Pharmatech (India) Private Limited (Director, since 30 Apr 2021, revenue ₹137 Cr (FY 2025)).

Feng Wei was first appointed on 30 Apr 2021 as Director at Bld Pharmatech (India) Private Limited.

The current boards of Feng Wei's companies include Chandan Mahendra Bhatera (Bld Pharmatech (India) Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available